These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 17285396)
1. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Karakousis GC; Gimotty PA; Czerniecki BJ; Elder DE; Elenitsas R; Ming ME; Fraker DL; Guerry D; Spitz FR Ann Surg Oncol; 2007 May; 14(5):1596-603. PubMed ID: 17285396 [TBL] [Abstract][Full Text] [Related]
2. Predictors of regional nodal disease in patients with thin melanomas. Karakousis GC; Gimotty PA; Botbyl JD; Kesmodel SB; Elder DE; Elenitsas R; Ming ME; Guerry D; Fraker DL; Czerniecki BJ; Spitz FR Ann Surg Oncol; 2006 Apr; 13(4):533-41. PubMed ID: 16523360 [TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421 [TBL] [Abstract][Full Text] [Related]
4. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103 [TBL] [Abstract][Full Text] [Related]
5. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755 [TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957 [TBL] [Abstract][Full Text] [Related]
7. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Kesmodel SB; Karakousis GC; Botbyl JD; Canter RJ; Lewis RT; Wahl PM; Terhune KP; Alavi A; Elder DE; Ming ME; Guerry D; Gimotty PA; Fraker DL; Czerniecki BJ; Spitz FR Ann Surg Oncol; 2005 Jun; 12(6):449-58. PubMed ID: 15864482 [TBL] [Abstract][Full Text] [Related]
8. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306 [TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331 [TBL] [Abstract][Full Text] [Related]
13. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039 [TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216 [TBL] [Abstract][Full Text] [Related]
15. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885 [TBL] [Abstract][Full Text] [Related]
16. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039 [TBL] [Abstract][Full Text] [Related]
17. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515 [TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Nahabedian MY; Tufaro AP; Manson PN Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009 [TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node status in melanoma: a valuable prognostic factor? Topar G; Eisendle K; Zelger B; Fritsch P Br J Dermatol; 2006 Jun; 154(6):1080-7. PubMed ID: 16704637 [TBL] [Abstract][Full Text] [Related]
20. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Carlson GW; Page AJ; Cohen C; Parker D; Yaar R; Li A; Hestley A; Delman KA; Murray DR Ann Surg; 2008 Sep; 248(3):378-86. PubMed ID: 18791358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]